Influence of antitumor drugs on the expression of Fas system in SW480 colon cancer cells

Zhu, Qing; Liu, Jiyong; Yang, Chen; Xu, Hui; Zhang, An-zhong; Yi, Chenju; Wang, Hongbo; Qin, Chengyong; Li, Yanqing

doi:10.1097/01.meg.0000231750.68513.6c

Cited by 9 publications

(9 citation statements)

References 19 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some Studies have shown that some tumor cells such as colon cancer, gastric cancer, pancreatic cancer express FasL [6,7] . Tumor specific antigen induces tumor infiltrating lymphocytes (TILs) to express high level of Fas, so that T lymphocytes are sensitive to apoptosis [8] .…”

Section: Discussionmentioning

confidence: 99%

T Cell Apoptosis Was Inhibited by Fas of Antisense Oligonucleotide

Zheng¹,

Jiang²,

Ge³

et al. 2010

2010 4th International Conference on Bioinformatics and Biomedical Engineering

View full text Add to dashboard Cite

We investigate the effect of specific antisense oligodeoxynucleotide (ASO DN) inhibition of Fas expression on T cell apoptosis induced by gastric carcinoma cell . Fas receptor (Fas) and Fas ligand (FasL) expressed by the gastric carcinoma cell line SGC-7901 and Jurkat T cells were detected by flow cytometry (FCM) and the ability of FasL-inducing T cell apoptosis was tested by co-culture assay in vitro with SGC-7901 cells and Jurkat T cells. The Jurkat cells were transfected with Fas-ASODN using lipofectin, and the effects of Fas-ASODN on Fas mRNA level, Fas expression on T cells surface, and apoptosis were investigated by RT-PCR, FCM and co-culture assay, respectively. SGC-7901 cells expressing functional FasL could induce the apoptosis of Jurkat cells as demonstrated by co-culture assays. After the Jurkat cells were transfected with Fas ASODN, the level of Fas mRNA, the expression rate of Fas and the apoptotic rate induced by gastric carcinoma cells were all decreased. Gastric carcinoma cells expressing FasL can induce apoptosis in Fas-expressing T cells, indicating that transfection of Fas ASODN can partially convert the immune inhibitory condition induced by gastric carcinoma cells. Fas ASODN may be a useful tool in the armamentarium of tumor immune therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

T Cell Apoptosis Was Inhibited by Fas of Antisense Oligonucleotide

Zheng¹,

Jiang²,

Ge³

et al. 2010

2010 4th International Conference on Bioinformatics and Biomedical Engineering

View full text Add to dashboard Cite

show abstract

“…Studies have shown that some tumor cells such as colon cancer, gastric cancer, pancreatic cancer express FasL [7][8][9][10]. Tumor specific antigen induces tumor infiltrating lymphocytes (TILs) to express high level of Fas, so that T lymphocytes are sensitive to apoptosis [11].…”

Section: Discussionmentioning

confidence: 99%

Effects of specific antisense oligonucleotide inhibition of Fas expression on T cell apoptosis induced by Fas ligand

Mao

Liu²,

Zhang³

et al. 2007

International Immunopharmacology

View full text Add to dashboard Cite

“…Shen et al demonstrated that low-dose, metronomic chemotherapy with Cis (0.6 mg/kg/day) dramatically inhibits tumor growth without apparent body weight loss and significant upregulation of Fas (CD95) mRNA and protein in SW480 colon cancer cells and oral cancer cell lines. It is possible for low-dose Cis to attenuate inflammatory responses by inducing Fas expression on effector T cells (21–23). We found that although 5-FU at 10 mg/kg demonstrated moderate antitumor effects, no severe side effects were observed.…”

Section: Discussionmentioning

confidence: 99%

Antitumor and immunomodulatory effects of low-dose 5-FU on hepatoma 22 tumor-bearing mice

et al. 2014

View full text Add to dashboard Cite

Low-dose 5-fluorouracil (5-FU), a widely used chemotherapeutic, has been reported to have immunomodulatory effects. This study aimed to evaluate the optimal dose of 5-FU that produces antitumor and immunomodulatory effects. In a hepatoma 22 tumor-bearing mouse model, 0, 10, 20 and 40 mg/kg 5-FU (i.p.) was administered for 10 days. Tumor weight and volume were measured, thymus index (TI) and spleen index (SI) were calculated, and the number of white blood cells (WBCs) and lymphocytes (LYs) were counted following treatment. The percentages of CD3+, CD4+, CD8+ and natural killer (NK) cells were measured by flow cytometry. In addition, the body weights of the mice were measured and the average diet consumption was calculated. Administration of 5-FU produced a potent antitumor effect in a dose-dependent manner (P<0.01). At 20 and 40 mg/kg, a significant reduction of body weight and food consumption was observed. TI and SI decreased in the 20- and 40-mg/kg groups (P<0.01) for 10 days. The number of WBCs significantly decreased in each group (P<0.01); however, the number of LYs only decreased in the 40-mg/kg group (P<0.01). Percentages of CD3+ and CD4+ cells were increased in the 10- and 20-mg/kg groups (P<0.01). Thus, 5-FU at 10 mg/kg inhibits tumor growth while maintaining the immune function of the mice. 5-FU may exert its antitumor effect at a low dose with low toxicity and stimulate the host immune system. Future clinical trials taking into account the immunostimulatory capacity of chemotherapeutic agents are desirable for certain patients.

show abstract

Influence of antitumor drugs on the expression of Fas system in SW480 colon cancer cells

Cited by 9 publications

References 19 publications

T Cell Apoptosis Was Inhibited by Fas of Antisense Oligonucleotide

T Cell Apoptosis Was Inhibited by Fas of Antisense Oligonucleotide

Effects of specific antisense oligonucleotide inhibition of Fas expression on T cell apoptosis induced by Fas ligand

Antitumor and immunomodulatory effects of low-dose 5-FU on hepatoma 22 tumor-bearing mice

Contact Info

Product

Resources

About